Eurofins Expands Its Biopharmaceutical Products Testing Footprint with an Outsourcing Agreement with Astellas in Japan

LUXEMBOURG--()--Regulatory News:

Eurofins (Paris:ERF)

Eurofins Scientific (EUFI.PA), a global leader in biopharmaceutical products testing services, announces that it has signed an outsourcing agreement with Astellas to outsource one of its internal testing laboratories Astellas Analytical Science Laboratories, Inc. (“ASL”).

ASL was established in 1996 as the core pharmaceutical product testing provider for Astellas Pharma Inc., one of the largest pharmaceutical companies in Japan. ASL offers analytical testing services that allow high-quality pharmaceuticals to enter the market. The company provides quality assessment of raw materials, drug substances and preparations related to drug approval applications. It also offers quality evaluation of formulation, stability evaluation, test method validation, physicochemical testing and microbiological testing using the latest analytical instruments available, including Cell Based Assay (CBA) for antibodies. ASL is located in Kyoto and employs more than 140 staff. As part of this outsourcing program, Astellas has committed to provide ASL work covering its current capacity for an agreed period of time as the company invests in further capabilities and staff to serve a wider range of clients.

ASL will be Eurofins’ first laboratory in Japan offering test services with the Good Manufacturing Practice (GMP) standard. It will become a key laboratory for the Group’s global GMP laboratory network, counting already more than 30 GMP sites in Europe, India and the USA. This outsourcing deal with Astellas provides Eurofins with a valuable entry into the biopharmaceutical products testing market in Japan. The outsourcing of this highly reputed laboratory expands the Group’s growing footprint in Asia Pacific, and provides a good platform to further expand in the biopharmaceutical products testing market in Asia.

Comment from Dr. Gilles Martin, Eurofins CEO: “We are very pleased that Astellas has entrusted Eurofins with its high quality internal laboratory, ASL. This is recognition of the high scientific and quality level of Eurofins’ network of GMP Biopharma product testing laboratories. With ASL and our other GMP sites we are committed to providing Astellas and our expanding group of clients in the APAC region with continued unmatched high level of service. We look forward to welcoming ASL to Eurofins’ family of businesses. We are very excited to collaborate with Astellas Pharma Inc., one of the most innovative pharmaceutical companies in the world, and are eager to develop a long term mutually-beneficial relationship with them.”

For more information, please visit www.eurofins.com.

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 35,000 staff in more than 400 laboratories across 44 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

Contacts

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Contacts

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com